Company
Eisai
Eisai has 39 drugs tracked on RxWires: 5 post-market, 5 in Phase 3, 2 in Phase 2/3, 4 in Phase 2, 6 in Phase 1/2, 16 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Lysozyme hydrochloride | Post-Market | COPD |
| Zonegran | Post-Market | Epilepsy |
| Donepezil | Post-Market | Alzheimer's Disease |
| Perampanel Oral Tablet | Post-Market | Epilepsy |
| Fospropofol disodium | Post-Market | Procedural Sedation |
| rabeprazole sodium | Phase 3 | Heartburn |
| Lecanemab IV | Phase 3 | Early Alzheimer's Disease |
| Zonisamide | Phase 3 | Epilepsy |
| E7777 9 mcg/kg | Phase 3 | Persistent or Recurrent Cutaneous T-Cell Lymphoma |
| E2007 | Phase 3 | Partial Onset Seizures |
| E3810 | Phase 2/3 | Refractory Reflux Esophagitis |
| Eszopiclone 1 mg | Phase 2/3 | Primary Insomnia |
| Decitabine | Phase 2 | Renal Cell Carcinoma |
| Lemborexant 10 mg | Phase 2 | Alzheimer Disease |
| Irsenontrine | Phase 2 | Dementia With Lewy Bodies |
| Lenvatinib | Phase 2 | Unresectable Stage III |
| Eribulin mesylate | Phase 1/2 | Metastatic Breast Cancer |
| E7449 alone | Phase 1/2 | Malignant Solid Tumour |
| E7386 | Phase 1/2 | Endometrial Neoplasms |
| E7389-LF | Phase 1/2 | Solid Neoplasms |
| Golvatinib | Phase 1/2 | Advanced Solid Tumors |
| Nivolumab | Phase 1/2 | Metastatic Breast Cancer |
| Tazemetostat | Phase 1 | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma |
| EA1080 | Phase 1 | Healthy Volunteers |
| E7050 | Phase 1 | Healthy Subjects |
| E6130 | Phase 1 | Japanese Healthy Adult Male Participants |
| E7080 | Phase 1 | Non-small-cell Lung Cancer |
| E3112 | Phase 1 | Healthy Male Volunteers |
| E7090 | Phase 1 | Tumors |
| E7130 | Phase 1 | Solid Tumors |
| E2086 | Phase 1 | |
| Tasurgratinib | Phase 1 | Hepatic Impairment |
| Palbociclib (75, 100, 125 milligram [mg]) | Phase 1 | Receptors, Estrogen |
| Bexarotene | Phase 1 | Thyroid Cancer |
| E2511 | Phase 1 | Healthy Volunteers |
| Avatrombopag | Phase 1 | Healthy Participants |
| E2730 | Phase 1 | Healthy Participants |
| 10-mg dose of E5501 2G tablet | Phase 1 | Idiopathic Thrombocytopenic Purpura |
| Lorcaserin | Not Applicable | Obesity |
Latest
No recent events.
Follow Eisai on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.